Brand Institute, announced its successful partnership with Arvinas, Inc. on the development of the nonproprietary name bavdegalutamide. Bavdegalutamide, also referred to as ARV-110, was published as a recommended INN in April of 2022. The product was granted fast-track designation by the FDA in May of 2019 for the treatment of metastatic castration-resistant prostate cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.67 USD | -2.95% | -3.82% | -37.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.63% | 1.76B | |
+18.15% | 124B | |
+18.02% | 112B | |
+3.38% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-16.80% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Brand Institute Partners on Nonproprietary Name for Novel Protein Degrader Under Development by Arvinas, Inc